Actio Biosciences

Actio Biosciences is developing precision medicines for the treatment of rare genetic diseases, including CMT Type 2C, by targeting underlying causes of disease with small molecules.

Actio Biosciences is a proud STAR Alliance partner of the CMTA. Together, we are committed to advancing educational initiatives, generating awareness of emerging treatment options, supporting CMT research, and uniting around a shared goal of accelerating progress for the CMT community. In addition to our scientific collaboration, we actively participate in fundraising efforts such as the Walk 4CMT to help drive meaningful impact beyond the lab.